ELISA/ACT Biotechnologies LLC

EAB has completed successful community-based, randomized outcome studies on fibromyalgia (FM), chronic fatigue (CFIDS), and Type 1 & 2 diabetes, proving the validity and reliability of the LRA by ELISA/ACT program.

A Novel Treatment for Fibromyalgia Improves Clinical Outcomes in a Community-Based Study

Determining the Role of Food/Environmental Sensitivities in Reducing Risk Factors in Patients with NIDDM

Phone: 1.800.553.5472 • E-mail: clientservices@elisaact.com • Search the Site •